Over 5,000 participants from more than 50 countries and a total of over 30,000 official meetings – that was the outcome of this year's edition of the international BIO-Europe conference in Munich. The Czech Republic was represented by the companies IOCB Tech, i&i Prague, and i&i Biotech Fund (i&i Bio), which are entities associated with the IOCB Tech Group under the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences. The Czech stand at the event was also supported by representatives of the Consulate General of the Czech Republic in Munich.

“IOCB Tech Group regularly participates in BIO-Europe. It is a useful opportunity for us to meet with leading representatives of the biotech, medtech, and life sciences world, as well as investors and scientific research clusters. Thanks also go to the organizers, the EBD Group,” said Martin Fusek, director of IOCB Tech.

BIO-Europe represents a great opportunity for us to meet startups at the forefront of Biotech. Specially, in the CEE region we have found great founders who are shaking the field with their innovative technologies. The event also gives us a chance to reach out to startups which might not have been ready for investment when we originally talked to them, but after some time it is fascinating to see their progress,” adds Roberto Fernandez Alvarez, who represented the incubator i&i Prague with other colleagues.

“This year's BIO-Europe was also unique due to the inclusion of a new section of panel discussions on so-called translational funds. These are investors who provide fund financing for the translational phase of research and the technology transfer process. Besides our i&i Bio, four other funds from Germany, Austria, and Belgium were presented, which were also established at significant scientific institutions,” says Jaromír Zahrádka, director of i&i Biotech Fund, adding: “It is evident that such funds have their place in the European venture capital market and often become the initial investor in new projects and biotechnological spin-off companies, which then get the chance to appeal to a broader group of less specialized investors.”

The IOCB Tech team conducted more than a hundred meetings and negotiations over three days. “We are particularly grateful for the discussion with the EBD Group regarding the potential hosting of the BIO-Europe conference in Prague, and we are pleased that this vision is also supported by significant clusters such as LISAvienna – Life Science Austria Vienna, BioM Biotech Cluster, Biosaxony association, and many others,” added Martin Opatrný, spokesperson for IOCB Tech.

Discussions on cooperation also took place, for example, with the company Symeres, a leading research organization focused on the discovery and development of new drugs. Representatives of the Consulate General in Munich also expressed their support for the IOCB Tech Group, whose visit was a significant recognition of the activities of the IOCB Tech Group.

“We are glad to be part of this significant event and present, thanks to IOCB Tech, Czech excellence in the field of life sciences and pharmacy, and thus show the world the innovations and potential of Czech science and technology transfer,” said consul Lukáš Opatrný from the Consulate General of the Czech Republic in Munich.

BIO-Europe is an annual meeting of visionaries, innovators, and experts in the field of biotechnology and pharmaceutical research from around the world. Over the past 29 years, BIO-Europe has grown not only in size but especially in becoming the flagship of European biotech. Its international reach is a symbolic gateway to the global life science community.